Skip to main content
Premium Trial:

Request an Annual Quote

Advion Reaches OEM, Distribution Deal with CAMAG for TLC/MS Interface Product

NEW YORK (GenomeWeb News) – Advion said on Monday it has signed an exclusive original equipment manufacturing and distribution partnership deal with Swiss firm CAMAG for Advion's TLC/MS interface product.

The two companies plan to commercialize a combined system to Advion's Synthetic Organic Chemistry and Peptide Synthesis global market segments, Advion said, adding it has exclusive marketing and support rights in certain geographies, including North America and parts of Europe.

"TLC is used in reaction monitoring, flash method development … solvent selection, flash fraction confirmation, and impurity profiling," David Patteson, CEO of Advion, said in a statement. "The combination of the CAMAG TLC-MS Interface with the Advion expression CMS is a perfect integration of best-in-class chemist assay tools."

The expression compact mass spectrometer is targeted for the discovery research and process development synthetic organic chemistry market and can provide rapid compound confirmation in normal phase chromatography fractions.

Advion plans to launch the combined system at conferences in March and April, the Ithaca, NY-based company said.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.